Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), seeking approval for its proprietary, selective cortisol modulator, ...
US biotech Corcept Therapeutics (Nasdaq: CORT) said the American medicines regulator has issued a complete response letter rejecting its application for relacorilant in hypertension secondary to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback